Tuis207940 • KRX
add
Samsung Biologics Co Ltd
Vorige sluiting
₩1 000 000,00
Dagwisseling
₩1 005 000,00 - ₩1 044 000,00
Jaarwisseling
₩721 000,00 - ₩1 113 000,00
Markkapitalisasie
72,03 bn KRW
Gemiddelde volume
71,47 k
P/V-verhouding
68,43
Dividend-opbrengs
-
Marknuus
Finansieel
Inkomstestaat
Inkomste
Netto inkomste
| (KRW) | Sep. 2024info | J/J-verandering |
|---|---|---|
Inkomste | 1,19 bn | 14,81% |
Bedryfskoste | 202,29 mjd | 11,50% |
Netto inkomste | 264,47 mjd | 10,03% |
Netto winsgrens | 22,28 | -4,17% |
Wins per aandeel | 3,72 k | 10,07% |
EBITDA | 495,40 mjd | 8,39% |
Effektiewe belastingkoers | 9,12% | — |
Balansstaat
Totale bates
Totale aanspreeklikheid
| (KRW) | Sep. 2024info | J/J-verandering |
|---|---|---|
Kontant en korttermynbeleggings | 988,11 mjd | -45,63% |
Totale bates | 16,03 bn | 0,87% |
Totale aanspreeklikheid | 5,43 bn | -14,30% |
Totale ekwiteit | 10,59 bn | — |
Uitstaande aandele | 71,17 m | — |
Prys om te bespreek | 6,72 | — |
Opbrengs op bates | 5,23% | — |
Opbrengs op kapitaal | 7,18% | — |
Kontantvloei
Netto kontantverandering
| (KRW) | Sep. 2024info | J/J-verandering |
|---|---|---|
Netto inkomste | 264,47 mjd | 10,03% |
Kontant van bedrywe | 740,39 mjd | 154,07% |
Kontant van beleggings | -437,12 mjd | -17,41% |
Kontant van finansiering | -713,37 mjd | -297,72% |
Netto kontantverandering | -433,28 mjd | -69,49% |
Beskikbare kontantvloei | -12,12 mjd | -237,42% |
Meer oor
Samsung Biologics Co., Ltd. is a global contract development and manufacturing organization headquartered in Songdo, Incheon, South Korea. The biotech division of Samsung Group, its core services range from late discovery to large-scale commercial manufacturing. The company focuses on monoclonal antibodies, bispecific antibodies, antibody-drug conjugates, and mRNA vaccines.
The company has partnered with pharmaceutical companies such as Pfizer, GlaxoSmithKline, Eli Lilly, AstraZeneca and Bristol-Myers Squibb. Wikipedia
HUB
Gestig
2011
Webwerf
Werknemers
4 744
